BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

540 related articles for article (PubMed ID: 24484606)

  • 1. Targeted prostate cancer screening in BRCA1 and BRCA2 mutation carriers: results from the initial screening round of the IMPACT study.
    Bancroft EK; Page EC; Castro E; Lilja H; Vickers A; Sjoberg D; Assel M; Foster CS; Mitchell G; Drew K; Mæhle L; Axcrona K; Evans DG; Bulman B; Eccles D; McBride D; van Asperen C; Vasen H; Kiemeney LA; Ringelberg J; Cybulski C; Wokolorczyk D; Selkirk C; Hulick PJ; Bojesen A; Skytte AB; Lam J; Taylor L; Oldenburg R; Cremers R; Verhaegh G; van Zelst-Stams WA; Oosterwijk JC; Blanco I; Salinas M; Cook J; Rosario DJ; Buys S; Conner T; Ausems MG; Ong KR; Hoffman J; Domchek S; Powers J; Teixeira MR; Maia S; Foulkes WD; Taherian N; Ruijs M; Helderman-van den Enden AT; Izatt L; Davidson R; Adank MA; Walker L; Schmutzler R; Tucker K; Kirk J; Hodgson S; Harris M; Douglas F; Lindeman GJ; Zgajnar J; Tischkowitz M; Clowes VE; Susman R; Ramón y Cajal T; Patcher N; Gadea N; Spigelman A; van Os T; Liljegren A; Side L; Brewer C; Brady AF; Donaldson A; Stefansdottir V; Friedman E; Chen-Shtoyerman R; Amor DJ; Copakova L; Barwell J; Giri VN; Murthy V; Nicolai N; Teo SH; Greenhalgh L; Strom S; Henderson A; McGrath J; Gallagher D; Aaronson N; Ardern-Jones A; Bangma C; Dearnaley D; Costello P; Eyfjord J; Rothwell J; Falconer A; Gronberg H; Hamdy FC; Johannsson O; Khoo V; Kote-Jarai Z; Lubinski J; Axcrona U; Melia J; McKinley J; Mitra AV; Moynihan C; Rennert G; Suri M; Wilson P; Killick E; ; Moss S; Eeles RA
    Eur Urol; 2014 Sep; 66(3):489-99. PubMed ID: 24484606
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Interim Results from the IMPACT Study: Evidence for Prostate-specific Antigen Screening in BRCA2 Mutation Carriers.
    Page EC; Bancroft EK; Brook MN; Assel M; Hassan Al Battat M; Thomas S; Taylor N; Chamberlain A; Pope J; Raghallaigh HN; Evans DG; Rothwell J; Maehle L; Grindedal EM; James P; Mascarenhas L; McKinley J; Side L; Thomas T; van Asperen C; Vasen H; Kiemeney LA; Ringelberg J; Jensen TD; Osther PJS; Helfand BT; Genova E; Oldenburg RA; Cybulski C; Wokolorczyk D; Ong KR; Huber C; Lam J; Taylor L; Salinas M; Feliubadaló L; Oosterwijk JC; van Zelst-Stams W; Cook J; Rosario DJ; Domchek S; Powers J; Buys S; O'Toole K; Ausems MGEM; Schmutzler RK; Rhiem K; Izatt L; Tripathi V; Teixeira MR; Cardoso M; Foulkes WD; Aprikian A; van Randeraad H; Davidson R; Longmuir M; Ruijs MWG; Helderman van den Enden ATJM; Adank M; Williams R; Andrews L; Murphy DG; Halliday D; Walker L; Liljegren A; Carlsson S; Azzabi A; Jobson I; Morton C; Shackleton K; Snape K; Hanson H; Harris M; Tischkowitz M; Taylor A; Kirk J; Susman R; Chen-Shtoyerman R; Spigelman A; Pachter N; Ahmed M; Ramon Y Cajal T; Zgajnar J; Brewer C; Gadea N; Brady AF; van Os T; Gallagher D; Johannsson O; Donaldson A; Barwell J; Nicolai N; Friedman E; Obeid E; Greenhalgh L; Murthy V; Copakova L; Saya S; McGrath J; Cooke P; Rønlund K; Richardson K; Henderson A; Teo SH; Arun B; Kast K; Dias A; Aaronson NK; Ardern-Jones A; Bangma CH; Castro E; Dearnaley D; Eccles DM; Tricker K; Eyfjord J; Falconer A; Foster C; Gronberg H; Hamdy FC; Stefansdottir V; Khoo V; Lindeman GJ; Lubinski J; Axcrona K; Mikropoulos C; Mitra A; Moynihan C; Rennert G; Suri M; Wilson P; Dudderidge T; ; Offman J; Kote-Jarai Z; Vickers A; Lilja H; Eeles RA
    Eur Urol; 2019 Dec; 76(6):831-842. PubMed ID: 31537406
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Targeted prostate cancer screening in men with mutations in BRCA1 and BRCA2 detects aggressive prostate cancer: preliminary analysis of the results of the IMPACT study.
    Mitra AV; Bancroft EK; Barbachano Y; Page EC; Foster CS; Jameson C; Mitchell G; Lindeman GJ; Stapleton A; Suthers G; Evans DG; Cruger D; Blanco I; Mercer C; Kirk J; Maehle L; Hodgson S; Walker L; Izatt L; Douglas F; Tucker K; Dorkins H; Clowes V; Male A; Donaldson A; Brewer C; Doherty R; Bulman B; Osther PJ; Salinas M; Eccles D; Axcrona K; Jobson I; Newcombe B; Cybulski C; Rubinstein WS; Buys S; Townshend S; Friedman E; Domchek S; Ramon Y Cajal T; Spigelman A; Teo SH; Nicolai N; Aaronson N; Ardern-Jones A; Bangma C; Dearnaley D; Eyfjord J; Falconer A; Grönberg H; Hamdy F; Johannsson O; Khoo V; Kote-Jarai Z; Lilja H; Lubinski J; Melia J; Moynihan C; Peock S; Rennert G; Schröder F; Sibley P; Suri M; Wilson P; Bignon YJ; Strom S; Tischkowitz M; Liljegren A; Ilencikova D; Abele A; Kyriacou K; van Asperen C; Kiemeney L; ; Easton DF; Eeles RA
    BJU Int; 2011 Jan; 107(1):28-39. PubMed ID: 20840664
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A prospective prostate cancer screening programme for men with pathogenic variants in mismatch repair genes (IMPACT): initial results from an international prospective study.
    Bancroft EK; Page EC; Brook MN; Thomas S; Taylor N; Pope J; McHugh J; Jones AB; Karlsson Q; Merson S; Ong KR; Hoffman J; Huber C; Maehle L; Grindedal EM; Stormorken A; Evans DG; Rothwell J; Lalloo F; Brady AF; Bartlett M; Snape K; Hanson H; James P; McKinley J; Mascarenhas L; Syngal S; Ukaegbu C; Side L; Thomas T; Barwell J; Teixeira MR; Izatt L; Suri M; Macrae FA; Poplawski N; Chen-Shtoyerman R; Ahmed M; Musgrave H; Nicolai N; Greenhalgh L; Brewer C; Pachter N; Spigelman AD; Azzabi A; Helfand BT; Halliday D; Buys S; Ramon Y Cajal T; Donaldson A; Cooney KA; Harris M; McGrath J; Davidson R; Taylor A; Cooke P; Myhill K; Hogben M; Aaronson NK; Ardern-Jones A; Bangma CH; Castro E; Dearnaley D; Dias A; Dudderidge T; Eccles DM; Green K; Eyfjord J; Falconer A; Foster CS; Gronberg H; Hamdy FC; Johannsson O; Khoo V; Lilja H; Lindeman GJ; Lubinski J; Axcrona K; Mikropoulos C; Mitra AV; Moynihan C; Ni Raghallaigh H; Rennert G; Collier R; ; Offman J; Kote-Jarai Z; Eeles RA
    Lancet Oncol; 2021 Nov; 22(11):1618-1631. PubMed ID: 34678156
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Imaging-based prostate cancer screening among BRCA mutation carriers-results from the first round of screening.
    Segal N; Ber Y; Benjaminov O; Tamir S; Yakimov M; Kedar I; Rosenbaum E; Sela S; Ozalvo R; Shavit-Grievink L; Keder D; Baniel J; Margel D
    Ann Oncol; 2020 Nov; 31(11):1545-1552. PubMed ID: 32958357
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Prostate Cancer Risks for Male BRCA1 and BRCA2 Mutation Carriers: A Prospective Cohort Study.
    Nyberg T; Frost D; Barrowdale D; Evans DG; Bancroft E; Adlard J; Ahmed M; Barwell J; Brady AF; Brewer C; Cook J; Davidson R; Donaldson A; Eason J; Gregory H; Henderson A; Izatt L; Kennedy MJ; Miller C; Morrison PJ; Murray A; Ong KR; Porteous M; Pottinger C; Rogers MT; Side L; Snape K; Walker L; Tischkowitz M; Eeles R; Easton DF; Antoniou AC
    Eur Urol; 2020 Jan; 77(1):24-35. PubMed ID: 31495749
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The role of the prostate cancer gene 3 urine test in addition to serum prostate-specific antigen level in prostate cancer screening among breast cancer, early-onset gene mutation carriers.
    Cremers RG; Eeles RA; Bancroft EK; Ringelberg-Borsboom J; Vasen HF; Van Asperen CJ; ; Schalken JA; Verhaegh GW; Kiemeney LA
    Urol Oncol; 2015 May; 33(5):202.e19-28. PubMed ID: 25746941
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Psychosocial impact of undergoing prostate cancer screening for men with BRCA1 or BRCA2 mutations.
    Bancroft EK; Saya S; Page EC; Myhill K; Thomas S; Pope J; Chamberlain A; Hart R; Glover W; Cook J; Rosario DJ; Helfand BT; Hutten Selkirk C; Davidson R; Longmuir M; Eccles DM; Gadea N; Brewer C; Barwell J; Salinas M; Greenhalgh L; Tischkowitz M; Henderson A; Evans DG; Buys SS; ; ; Eeles RA; Aaronson NK
    BJU Int; 2019 Feb; 123(2):284-292. PubMed ID: 29802810
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Male BRCA1 and BRCA2 mutation carriers: a pilot study investigating medical characteristics of patients participating in a prostate cancer prevention clinic.
    Horsburgh S; Matthew A; Bristow R; Trachtenberg J
    Prostate; 2005 Oct; 65(2):124-9. PubMed ID: 15880530
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Prostate-specific antigen velocity in a prospective prostate cancer screening study of men with genetic predisposition.
    Mikropoulos C; Selkirk CGH; Saya S; Bancroft E; Vertosick E; Dadaev T; Brendler C; Page E; Dias A; Evans DG; Rothwell J; Maehle L; Axcrona K; Richardson K; Eccles D; Jensen T; Osther PJ; van Asperen CJ; Vasen H; Kiemeney LA; Ringelberg J; Cybulski C; Wokolorczyk D; Hart R; Glover W; Lam J; Taylor L; Salinas M; Feliubadaló L; Oldenburg R; Cremers R; Verhaegh G; van Zelst-Stams WA; Oosterwijk JC; Cook J; Rosario DJ; Buys SS; Conner T; Domchek S; Powers J; Ausems MG; Teixeira MR; Maia S; Izatt L; Schmutzler R; Rhiem K; Foulkes WD; Boshari T; Davidson R; Ruijs M; Helderman-van den Enden AT; Andrews L; Walker L; Snape K; Henderson A; Jobson I; Lindeman GJ; Liljegren A; Harris M; Adank MA; Kirk J; Taylor A; Susman R; Chen-Shtoyerman R; Pachter N; Spigelman A; Side L; Zgajnar J; Mora J; Brewer C; Gadea N; Brady AF; Gallagher D; van Os T; Donaldson A; Stefansdottir V; Barwell J; James PA; Murphy D; Friedman E; Nicolai N; Greenhalgh L; Obeid E; Murthy V; Copakova L; McGrath J; Teo SH; Strom S; Kast K; Leongamornlert DA; Chamberlain A; Pope J; Newlin AC; Aaronson N; Ardern-Jones A; Bangma C; Castro E; Dearnaley D; Eyfjord J; Falconer A; Foster CS; Gronberg H; Hamdy FC; Johannsson O; Khoo V; Lubinski J; Grindedal EM; McKinley J; Shackleton K; Mitra AV; Moynihan C; Rennert G; Suri M; Tricker K; ; Moss S; Kote-Jarai Z; Vickers A; Lilja H; Helfand BT; Eeles RA
    Br J Cancer; 2018 Jan; 118(2):266-276. PubMed ID: 29301143
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Initial Findings from a High Genetic Risk Prostate Cancer Clinic.
    Sessine MS; Das S; Park B; Salami SS; Kaffenberger SD; Kasputis A; Solorzano M; Luke M; Vince RA; Kaye DR; Borza T; Stoffel EM; Cobain E; Merajver SD; Jacobs MF; Milliron KJ; Caba L; van Neste L; Mondul AM; Morgan TM
    Urology; 2021 Oct; 156():96-103. PubMed ID: 34280438
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Magnetic Resonance Imaging-based Prostate Cancer Screening in Carriers of Pathogenic Germline Mutations: Interim Results from the Initial Screening Round of the Prostate Cancer Genetic Risk Evaluation and Screening Study.
    Amini AE; Hunter AE; Almashad A; Feng AJ; Patel ND; O'Dea MR; McCormick SR; Rodgers LH; Salari K
    Eur Urol Oncol; 2024 Mar; ():. PubMed ID: 38453598
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The association of BRCA1 and BRCA2 mutations with prostate cancer risk, frequency, and mortality: A meta-analysis.
    Oh M; Alkhushaym N; Fallatah S; Althagafi A; Aljadeed R; Alsowaida Y; Jeter J; Martin JR; Babiker HM; McBride A; Abraham I
    Prostate; 2019 Jun; 79(8):880-895. PubMed ID: 30900310
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Prostate Cancer Screening in a New Era of Genetics.
    Cheng HH; Pritchard CC; Montgomery B; Lin DW; Nelson PS
    Clin Genitourin Cancer; 2017 Dec; 15(6):625-628. PubMed ID: 28697982
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The role of germline mutations in the BRCA1/2 and mismatch repair genes in men ascertained for early-onset and/or familial prostate cancer.
    Maia S; Cardoso M; Paulo P; Pinheiro M; Pinto P; Santos C; Pinto C; Peixoto A; Henrique R; Teixeira MR
    Fam Cancer; 2016 Jan; 15(1):111-21. PubMed ID: 26289772
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Screening Men at Increased Risk for Prostate Cancer Diagnosis: Model Estimates of Benefits and Harms.
    Gulati R; Cheng HH; Lange PH; Nelson PS; Etzioni R
    Cancer Epidemiol Biomarkers Prev; 2017 Feb; 26(2):222-227. PubMed ID: 27742670
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Prostate cancer: What is the real IMPACT of BRCA1/BRCA2 mutation?
    Clyne M
    Nat Rev Urol; 2014 Mar; 11(3):124. PubMed ID: 24492431
    [No Abstract]   [Full Text] [Related]  

  • 18. Elevated expression of Ki-67 identifies aggressive prostate cancers but does not distinguish BRCA1 or BRCA2 mutation carriers.
    Mitra AV; Jameson C; Barbachano Y; Sodha N; Kote-Jarai Z; Javed A; Bancroft E; Fletcher A; Cooper C; Peock S; ; Easton D; Eeles R; Foster CS
    Oncol Rep; 2010 Feb; 23(2):299-305. PubMed ID: 20043088
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Male BRCA mutation carriers: clinical characteristics and cancer spectrum.
    Ibrahim M; Yadav S; Ogunleye F; Zakalik D
    BMC Cancer; 2018 Feb; 18(1):179. PubMed ID: 29433453
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Prostate cancer risk, screening and management in patients with germline BRCA1/2 mutations.
    Rajwa P; Quhal F; Pradere B; Gandaglia G; Ploussard G; Leapman MS; Gore JL; Paradysz A; Tilki D; Merseburger AS; Morgan TM; Briganti A; Palapattu GS; Shariat SF
    Nat Rev Urol; 2023 Apr; 20(4):205-216. PubMed ID: 36600087
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 27.